Apogee Therapeutics

APGE

Market cap $6.19B

SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences.

Apogee Therapeutics, Inc. remains a Buy, driven by zumilokibart's potential in atopic dermatitis and recent positive Phase 2b data. Zumilokibart's efficacy matches leading biologics, with the key differentiator being 2–4 annual doses, pending maintenance data in 2025. The Blackstone collaboration secures up to $1.3B in funding, eliminating near-term dilution risk and supporting commercialization.

Apogee Enterprises (NASDAQ:APOG) has entered a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in non-dilutive capital, combining up to $800 million in synthetic royalty financing with as much as $500 million in senior corporate debt, giving the immunology developer runway to advance Phase 3 development and potential commercialization of its lead candidate zumilokibart. The financing structure pairs royalty-based capital tied to future product revenue with senior debt capacity.

Apogee Therapeutics revealed mixed results for its experimental eczema treatment Wednesday, and the stock dropped.

Apogee Therapeutics said on Wednesday it secured a financing deal with Blackstone Life Sciences worth up to $1.3 billion to support ​late-stage development and potential commercialization of its experimental eczema drug, ‌zumilokibart.

Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt

APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H 2026

SAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart on Wednesday, May 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m.

Apogee Therapeutics, Inc. has roughly doubled since October 2025, driven by promising data for the lead asset zumilokibart in atopic dermatitis. Zumi offers a significant compliance advantage with once-quarterly or twice-annual dosing, outperforming current biologics in efficacy and maintenance. Upcoming catalysts include Part B APEX data in 2Q26 and APG279 combination data in 2H26, with Phase 3 initiation and potential news vacuum thereafter.

Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis (AD) expected later this year: - APEX Phase 2 Part A 52-week data demonstrated durable maintenance and improved efficacy over time with every 3- and 6-month dosing in moderate-to-severe AD - APEX Phase 2 Part B 16-week data in AD expected in Q2 2026 - Following positive Phase 1b asthma results earlier this year, expansion plans are underway with additional trial details for asthma and eosinophilic esophagitis (EoE) expected later this year Strong cash position of $1.3B following successful public equity offering extending runway into 2029, through planned BLA filing for AD, subject to regulatory alignment SAN FRANCISCO and BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today provided pipeline progress and reported first quarter 2026 financial results. “We are off to a rapid start in 2026, reflecting the team's relentless focus on execution.